Company began recording revenue from Flora Sync LF5 in July 2026
Company expects to begin recording revenue from DARE to PLAY Sildenafil Cream in Q3 2026
Revenue from DARE to RECLAIM estradiol and progesterone intravaginal ring targeted to begin in 2027
Overview
U.S. women's health biotech reported Q2 revenue of $0.2 mln, up from prior year
Net loss for Q2 narrowed compared to same period last year
Company launched Flora Sync LF5, its first directly commercialized product, in July
Result Drivers
R&D services revenue - Q2 revenue increase was attributed to research and development services revenues from Gates Foundation agreements, partially offset by lower non-cash royalty revenues
Cost of revenues - Cost of revenues in Q2 reflected expenses from performing R&D services and medical education and awareness for commercialization of DARE to PLAY
Lower R&D expenses - R&D expenses declined mainly due to increased contra R&D expenses and reduced direct costs for Ovaprene Phase 3 and other programs
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Dare Bioscience Inc is $9.00, about 525% above its August 12 closing price of $1.44
DARE•
